PM
GNMK

Precept Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Precept Management’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-50,000
Closed -$736K – 104
2020
Q2 		$736K Sell
50,000
-44,000
-47% -$447K 0.14% 68
2020
Q1 		$387K Buy
+94,000
New +$441K 0.05% 100

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Precept Management's GNMK Position: Q3 2020 in Review

Precept Management sold out of GenMark Diagnostics, Inc (GNMK) in Q3 2020, closing a stake of 50,000 shares — an estimated $736K sold.

Precept Management first reported a position in GNMK in Q1 2020 and held it in 2 quarters. The position peaked at $736K in Q2 2020. 163 funds tracked by Wall St. Rank hold GNMK as of Q3 2020.

  • Precept Management reported no remaining GenMark Diagnostics, Inc position as of Q3 2020 after selling out during the quarter.
  • Precept Management sold 50,000 GenMark Diagnostics, Inc shares in Q3 2020, an estimated $736K.
  • Precept Management first reported a position in GenMark Diagnostics, Inc in Q1 2020 and held it in 2 quarters.
  • Precept Management's GenMark Diagnostics, Inc position peaked at $736K in Q2 2020.
  • 163 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2020.

Based on Precept Management's 13F filing for Q3 2020, filed 16 Nov 2020.